Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk

This is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.

Happy Thursday. My spin class soundtrack of mainly Kesha's music last night was more evidence that the 2016 aesthetic is back.

Stock futures are lower this morning. The three major indexes are coming off a winning session.

Here are five key things investors need to know to start the trading day:

Shares of Walmart slid more than 2% in premarket trading this morning after the company's guidance for the current fiscal year came in softer than anticipated.

Here's what to know:

Minutes from the Federal Reserve's January meeting released yesterday showed officials largely approved of holding interest rates steady. However, there was notable division within the central bank on where monetary policy should go next.

As CNBC's Jeff Cox reports, some Fed members said interest rates could come down further if inflation slides as they expect it to. Others said such easing may not be necessary for some time while they await clear signs that disinflation is taking place.

Speaking of the central bank: White House economic advisor Kevin Hassett told CNBC yesterday that the authors of a recent New York Fed paper should be "disciplined." Hassett said the study, which found that U.S. companies and consumers are absorbing most of the impacts from President Donald Trump's tariffs, was "the worst paper I've ever seen in the history of the Federal Reserve system."

Food and Drug Administration Commissioner Marty Makary warned yesterday that U.S. is falling behind China on early-stage drug development, saying the U.S. should streamline the process for beginning trials on new treatments.

In an interview with CNBC's Annika Kim Constantino, Makary also said that all drugs "should be over the counter" — with the exception of those that are unsafe, addictive or require monitoring. Some in the pharmaceutical industry have raised doubts about the effectiveness of such a move, warning that it could increase costs and decrease access for patients.

Meanwhile, Moderna said yesterday that the FDA agreed to review its experimental mRNA flu shot — a reversal from the regulator's prior refusal of the application. Moderna's shares jumped around 6% in yesterday's session following the announcement.

CNBC's Morning Squawk recaps the biggest stories investors should know before the stock market opens, every weekday morning.

Subscribe here to get access today.

Meta CEO Mark Zuckerberg took the stand yesterday in a landmark trial on social media and safety. As CNBC's Jonathan Vanian and Samantha Subin note, the Los Angeles trial is just one of several major court cases that are together being described as the social media industry's "Big Tobacco" moment.

In his testimony, Zuckerberg said that increasing users' time spent on Instagram was never a company goal, despite an email he sent in 2015 that seemed to make improving engagement a critical issue for the company. The Facebook founder also said he approached Apple CEO Tim Cook to talk about the "wellbeing of teens and kids."

Members of Zuckerberg's team were seen entering the courthouse wearing Meta's Ray-Ban artificial intelligence glasses, but Judge Carolyn B. Kuhl later threatened to hold anyone using smart glasses during the CEO's testimony in contempt of court. "If you have done that, you must delete that, or you will be held in contempt of the court," Kuhl said.

If you're flying United Airlines, you may soon earn fewer miles — unless you have one of the air carrier's credit cards.

United said Thursday that it will no longer reward customers flying basic economy who don't have the airline's credit card, following in the footsteps of American Airlines and Delta Air Lines. Card-holding travelers, meanwhile, will earn more points and receive frequent flyer discounts.

As CNBC's Leslie Josephs reports, the airline's changes mark some of the biggest adjustments to its frequent flyer program in more than a decade.

The Supreme Court could rule as soon as this week on Trump's tariffs. But as CNBC's Gabrielle Fonrouge and Natalie Rice report, the furniture industry likely won't be sitting pretty, regardless of the court's decision.

— CNBC's Melissa Repko, Annie Palmer, Jeff Cox, Annika Kim Constantino, Samantha Subin, Jonathan Vanian, Leslie Josephs, Gabrielle Fonrouge and Natalie Rice contributed to this report. Josephine Rozzelle edited this edition.